TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9716146

Group type: EXPERIMENTAL
Intervention: GBV‐C/HGV infection
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Sequence analysis of GBV‐C/HGV isolates
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis
Number of subjects: 91
Study: 18415455

Group type: EXPERIMENTAL
Intervention: Clonidine 5 mug/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2930802

Group type: EXPERIMENTAL
Intervention: High sensation seekers in the first run showed a tendency toward steeper slopes of the amplitude/stimulus intensity function (ASF).
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: High sensation seekers showed an influence of retesting on the slope of the ASF, leading to a decrease of the slope in the second run compared to the first run.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Low sensation seekers showed longer N1 latencies over the right hemisphere than over the left hemisphere.
Number of subjects: 33
Study: 790129

Group type: EXPERIMENTAL
Intervention: Bencyclan (Fludilat) administered intravenously at a dosage of 500 mg per day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 50
Study: 30545448

Group type: EXPERIMENTAL
Intervention: Incremental treatment (pre‐procedural cefazolin plus vancomycin, intraprocedural bacitracin pocket wash, and 2‐day post‐procedural oral cephalexin)
Number of subjects: 12842

Group type: COMPARATOR
Intervention: Conventional treatment (pre‐procedural cefazolin infusion)
Number of subjects: 12842

Group type: EXPERIMENTAL
Intervention: Incremental treatment
Number of subjects: 12842

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 12842
Study: 28550021

Group type: EXPERIMENTAL
Intervention: CPAP with best supportive care (BSC)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 148
Study: 26232540

Group type: EXPERIMENTAL
Intervention: 23vPPV vaccination
Number of subjects: 194
Study: 24124893

Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention (12 weeks, twice weekly, cardiovascular and strength training, relaxation)
Number of subjects: 216
Study: 20869141

Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham-exercise program
Number of subjects: 54
Study: 18533154

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17699351

Group type: EXPERIMENTAL
Intervention: Dialysate temperature at 35 degrees C (HD(35))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dialysate temperature at 37 degrees C (HD(37))
Number of subjects: 10
Study: 12664788

Group type: EXPERIMENTAL
Intervention: Mesacol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfasalazine
Number of subjects: 0
Study: 10953842

Group type: EXPERIMENTAL
Intervention: Betamethasone nasal drops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9169966

Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.5 mg alprazolam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8467286

Group type: EXPERIMENTAL
Intervention: rhGM‐CSF plus rHuEPO
Number of subjects: 18

Group type: COMPARATOR
Intervention: rhGM‐CSF alone (historical control)
Number of subjects: 18

Group type: COMPARATOR
Intervention: rhGM‐CSF alone (concurrent control)
Number of subjects: 18
Study: 3938925

Group type: EXPERIMENTAL
Intervention: Metrifonate treatment (MIT)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo (MIP)
Number of subjects: 399
Study: 30975376

Group type: EXPERIMENTAL
Intervention: Online dietary tool
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Setting ≥2 goals and engaging in self-monitoring
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Setting ≥2 goals
Number of subjects: 898
Study: 29068772

Group type: EXPERIMENTAL
Intervention: Media Aware program
Number of subjects: 184
Study: 27310942

Group type: EXPERIMENTAL
Intervention: Mental effort training (MET) with low-intensity physical exercise (30% MVC) for 12 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Conventional strength training (CST) with high-intensity muscle contractions for 12 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (CTRL) with no training
Number of subjects: 27
Study: 25139716

Group type: EXPERIMENTAL
Intervention: Minimally invasive reduction and percutaneous fixation (MIRPF)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 45
Study: 23818202

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with rehabilitation training
Number of subjects: 200

Group type: COMPARATOR
Intervention: Rehabilitation training alone
Number of subjects: 200
Study: 21078465

Group type: EXPERIMENTAL
Intervention: SBIRT (Screening, Brief Intervention, and Referral to Treatment) by emergency nurses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 18256325

Group type: EXPERIMENTAL
Intervention: IL-2 (9 million units/m²/day for 4 days followed 5 days later by 1.6 million units/m²/day for 10 days)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 376
Study: 16863482

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg on the evening before and 150 mg on the day of study drug administration, without food (treatment A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg on the evening before and 150 mg on the day of study drug administration, with food (treatment B)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Food alone (treatment C, control)
Number of subjects: 12
Study: 14644860

Group type: EXPERIMENTAL
Intervention: Oral pilocarpine (5 mg twice a day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 29

Group type: COMPARATOR
Intervention: Inferior puncta occlusion
Number of subjects: 29
Study: 11007680

Group type: EXPERIMENTAL
Intervention: 200 mg/wk of intravenous iron dextran (IVID) for 5 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 500 mg/wk of intravenous iron dextran (IVID) for 2 weeks
Number of subjects: 22
Study: 8820449

Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 8
Study: 1728443

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) combined with intravenous isosorbide dinitrate (ISDN; 5 mg/hr)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo combined with intravenous isosorbide dinitrate (ISDN; 5 mg/hr)
Number of subjects: 10
Study: 2877386

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 mg a day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study: 29546560

Group type: EXPERIMENTAL
Intervention: Transanal total mesorectal excision (Ta-TME)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Laparoscopic low anterior resection (L-LAR)
Number of subjects: 116
Study: 27097042

Group type: EXPERIMENTAL
Intervention: Carbohydrate-Protein (CHO-P; 0.8 g carbohydrate·kg body mass [BM-1]·h-1 plus 0.4 g protein·kg BM-1·h-1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Isocaloric Carbohydrate (CHO; 1.2 g carbohydrate·kg BM-1·h-1)
Number of subjects: 6
Study: 23553613

Group type: EXPERIMENTAL
Intervention: Office evaluation plus urodynamic testing (OE + UDS)
Number of subjects: 630

Group type: COMPARATOR
Intervention: Office evaluation (OE)
Number of subjects: 630
Study: 22387271

Group type: EXPERIMENTAL
Intervention: HUT + LBNP with added mental challenge (2 min before expected presyncope time)
Number of subjects: 5

Group type: COMPARATOR
Intervention: HUT + LBNP (control)
Number of subjects: 5
Study: 20636196

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) group
Number of subjects: 58

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 58
Study: 18702350

Group type: EXPERIMENTAL
Intervention: 0.3 mg pegaptanib sodium
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 1 mg pegaptanib sodium
Number of subjects: 95
Study: 15935650

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.5% bupivacaine plus fentanyl 100 microg
Number of subjects: 80
Study: 12511360

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% gel (1 ml)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Lidocaine 4% unpreserved eyedrops (0.5 ml)
Number of subjects: 107
Study: 10190222

Group type: EXPERIMENTAL
Intervention: Olanzapine therapy
Number of subjects: 1996

Group type: COMPARATOR
Intervention: Haloperidol therapy
Number of subjects: 1996
Study: 8926734

Group type: EXPERIMENTAL
Intervention: Passive inhalation of 100 and 200 mg freebase cocaine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous injection of 1 mg cocaine hydrochloride
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Passive exposure to sidestream smoke from crack smokers
Number of subjects: 6
Study: 2257862

Group type: EXPERIMENTAL
Intervention: Withdrawal of low-dose prednisolone (0.3-0.6 mg/kg body weight)
Number of subjects: 10
Study: 215304

Group type: EXPERIMENTAL
Intervention: Intrathoracic Bacillus Calmette-Guérin (BCG)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intrathoracic Bacillus Calmette-Guérin (BCG) plus levamisole
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Purified protein derivative conversion
Number of subjects: 100
Study: 30713154

Group type: EXPERIMENTAL
Intervention: Intensive term-time workers (> 12 h/w and in regular work)
Number of subjects: 2800

Group type: COMPARATOR
Intervention: Non-workers
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: Moderate workers (≤ 12 h/w and/or in irregular work)
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: Demographic factors
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 2800
Study: 28249624

Group type: EXPERIMENTAL
Intervention: Compassion-focused therapy (CFT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CFT
Number of subjects: 50

Group type: COMPARATOR
Intervention: CBT
Number of subjects: 50
Study: 25966065

Group type: EXPERIMENTAL
Intervention: Intracoronary transplantation of umbilical cord MSCs along with medication
Number of subjects: 59

Group type: COMPARATOR
Intervention: Medication only (control group)
Number of subjects: 59
Study: 23234753

Group type: EXPERIMENTAL
Intervention: RBANS Effort Index (EI)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Cutoff score of >4 for EI
Number of subjects: 128

Group type: COMPARATOR
Intervention: Overall cognitive functioning and symptoms of psychopathology
Number of subjects: 128
Study: 20306091

Group type: EXPERIMENTAL
Intervention: Simulation training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Apprenticeship training
Number of subjects: 16
Study: 19228659

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination ETN and MTX treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (severe RA)
Number of subjects: 0
Study: 16820633

Group type: EXPERIMENTAL
Intervention: Prima Plus stentless bioprosthesis
Number of subjects: 161

Group type: COMPARATOR
Intervention: C‐E Perimount stented bioprosthesis
Number of subjects: 161
Study: 12725261

Group type: EXPERIMENTAL
Intervention: Intravenous iron
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral iron
Number of subjects: 40
Study: 10673065

Group type: EXPERIMENTAL
Intervention: Niravoline (0.5 to 2 mg iv)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Niravoline (1.5 mg or 2 mg iv)
Number of subjects: 18
Study: 9326749

Group type: EXPERIMENTAL
Intervention: Ketoconazole (KTCZ)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 5-HT1A agonist ipsapirone (IPS)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 27
Study: 8452380

Group type: EXPERIMENTAL
Intervention: SDI test with adjuvant chemotherapy using tegafur and one of the following drugs: mitomycin C (MMC), adriamycin (ADM), or cisplatin (CDDP).
Number of subjects: 0
Study: 3526915

Group type: EXPERIMENTAL
Intervention: EMG feedback
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional physical therapy procedure (NDT)
Number of subjects: 12
Study: 27168018

Group type: EXPERIMENTAL
Intervention: Monopolar TURP
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Bipolar TURP
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Photoselective Vaporization of the Prostate (PVP)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 186
Study: 26926307

Group type: EXPERIMENTAL
Intervention: Radical Intravelar Veloplasty (RIVVP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: V‐Y Pushback Pharyngoplasty and Radical Intravelar Veloplasty (VYP+RIVVP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: RIVVP and VYP+RIVVP
Number of subjects: 20

Group type: COMPARATOR
Intervention: Palatal lengthening
Number of subjects: 20
Study: 23954938

Group type: EXPERIMENTAL
Intervention: Self-management intervention (standard)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Self-management intervention (relapse prevention)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 255
Study: 22830462

Group type: EXPERIMENTAL
Intervention: Early CCTA
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard evaluation
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 1000
Study: 20687924

Group type: EXPERIMENTAL
Intervention: Risk communication on cardiovascular disease (CVD) on top of standard managed care, including a simple explanation of causes, consequences, and prevention of CVD, with probabilities explained in natural frequencies and visualized by a population diagram.
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Risk communication on cardiovascular disease (CVD) on top of standard managed care.
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard managed care.
Number of subjects: 240
Study: 18034788

Group type: EXPERIMENTAL
Intervention: SSP+ (platelet additive solution with potassium and magnesium)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intersol (control platelet additive solution)
Number of subjects: 10
Study: 16899628

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg daily
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 12418614

Group type: EXPERIMENTAL
Intervention: Low-intensity night-time therapeutic electrical stimulation (TES) applied to the deltoid and biceps muscle from 6 to 12 months.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo stimulator applied to the opposite arm as control.
Number of subjects: 13
Study: 10512132

Group type: EXPERIMENTAL
Intervention: Oral etoposide, 50 mg/m2, days 1‐21
Number of subjects: 171

Group type: COMPARATOR
Intervention: Intravenous etoposide, 200 mg/m2, days 1‐3
Number of subjects: 171
Study: 7491386

Group type: EXPERIMENTAL
Intervention: neuroleptics
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 2037844

Group type: EXPERIMENTAL
Intervention: Caffeine doses (four different doses administered)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expectancy instructional set
Number of subjects: 0
Study: 6282192

Group type: EXPERIMENTAL
Intervention: Azlocillin plus Amikacin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cefotaxime plus Amikacin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Azlocillin plus Cefotaxime
Number of subjects: 40
Study: 30645635

Group type: EXPERIMENTAL
Intervention: Prasugrel 10mg/day for 1 year
Number of subjects: 2291
Study: 30879462

Group type: EXPERIMENTAL
Intervention: K-wire fixation (n=72)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Palmar plate fixation (n=30)
Number of subjects: 102
Study: 26792349

Group type: EXPERIMENTAL
Intervention: Complete mesocolic excision (CME), n=39
Number of subjects: 85
Study: 24210997

Group type: EXPERIMENTAL
Intervention: Imagined turning gait
Number of subjects: 5

Group type: COMPARATOR
Intervention: Imagined gait tasks (simple and complex)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Walking speed correlation
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Altered SMA activity during imagined turning
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Lowered activity in GP
Number of subjects: 5
Study: 23446658

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss (BWL) treatment
Number of subjects: 316

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 316
Study: 20089780

Group type: EXPERIMENTAL
Intervention: Whole-grain rye bread (minimum 240 g/d)
Number of subjects: 51
Study: 17947289

Group type: EXPERIMENTAL
Intervention: Joint attention intervention
Number of subjects: 35

Group type: COMPARATOR
Intervention: Symbolic play intervention
Number of subjects: 35
Study: 15629602

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MC) 15 mg/M(2)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Porfiromycin (POR) 40 mg/M(2)
Number of subjects: 128
Study: 12183719

Group type: EXPERIMENTAL
Intervention: Oral stimulation program (15 minutes of stimulation of oral structures, once per day for 10 days)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral stimulation program
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham stimulation program (control)
Number of subjects: 32
Study: 9891914

Group type: EXPERIMENTAL
Intervention: Living near cement kilns (Midlothian, Texas)
Number of subjects: 58
Study: 7845271

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 52

Group type: COMPARATOR
Intervention: Metoclopramide with dexamethasone
Number of subjects: 52
Study: 3041924

Group type: EXPERIMENTAL
Intervention: OM-8980
Number of subjects: 145

Group type: COMPARATOR
Intervention: Auranofin
Number of subjects: 145
Study: 29793053

Group type: EXPERIMENTAL
Intervention: Diet with sodium (0.8 g/d) and fluid (800 mL/d) restriction
Number of subjects: 53

Group type: COMPARATOR
Intervention: Unrestricted diet
Number of subjects: 53
Study: 27003301

Group type: EXPERIMENTAL
Intervention: 3.75 mg of Lupron
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 3.75 mg of Lupron and estrogen replacement
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Lupron
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Lupron and estrogen replacement
Number of subjects: 38
Study: 25106008

Group type: EXPERIMENTAL
Intervention: Regenerated Bone 12 months post-extraction (RB12)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Healed Bone (HB)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Regenerated Bone 6 months post-extraction (RB6)
Number of subjects: 216
Study: 22749295

Group type: EXPERIMENTAL
Intervention: Modified Oswestry Disability Index
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Modified Swiss Spinal Stenosis Scale (SSS)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Patient Specific Functional Scale
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Numeric Pain Rating Scale (NPRS)
Number of subjects: 55
Study: 20543733

Group type: EXPERIMENTAL
Intervention: Full range of motion (FRoM) testing
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Short range of motion (SRoM1) testing
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bilateral comparison (involved vs. uninvolved hand)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: FRoM and SRoM1 isokinetic testing
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dynamic weakness of the wrist extension-flexion apparatus
Number of subjects: 23
Study: 19011166

Group type: EXPERIMENTAL
Intervention: Coated archwires (as-received)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Retrieved coated archwires (after 4-6 weeks of use)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Retrieved coated archwires
Number of subjects: 10
Study: 15927936

Group type: EXPERIMENTAL
Intervention: Fortified milk (375 microg folic acid)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control milk (unfortified)
Number of subjects: 73
Study: 15347862

Group type: EXPERIMENTAL
Intervention: Slow breathing exercise for three months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fast breathing exercise for three months
Number of subjects: 60
Study: 10995594

Group type: EXPERIMENTAL
Intervention: L-arginine infusion at 100 mg/kg for 30 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: D-arginine infusion at 100 mg/kg for 30 min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: L-arginine infusion at 500 mg/kg for 30 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: D-arginine infusion at 500 mg/kg for 30 min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: L-arginine infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: D-arginine infusion
Number of subjects: 20
Study: 9315539

Group type: EXPERIMENTAL
Intervention: Enalapril (0.2 to 0.3 mg x kg[-1] x d[-1], maximum 15 mg) for 10 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo for 10 weeks
Number of subjects: 18
Study: 8299529

Group type: EXPERIMENTAL
Intervention: Nd: YAG pulsed laser intervention for desensitization
Number of subjects: 0
Study: 3511311

Group type: EXPERIMENTAL
Intervention: Insulin pump therapy (N = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intensive conventional insulin therapy (N = 11)
Number of subjects: 22
Study: 2500784

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist visits (11 physicians)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Peer-comparison feedback (10 physicians)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (10 physicians)
Number of subjects: 31
Study: 30728034

Group type: EXPERIMENTAL
Intervention: SPIRIT intervention (1-year programme including audit, feedback, goal setting, leadership programme, staff training, systems testing, researcher exchange)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: SPIRIT intervention (1-year programme)
Number of subjects: 6